The United States’ recent decision to impose a 25% tariff on specific Chinese made pharmaceutical ingredients could indirectly affect Indian pharmaceutical companies, industry analysts warn. Indian pharma firms currently source over 60% of their active pharmaceutical ingredient (API) needs from China. Although the US has targeted only Chinese imports with its tariffs, the move could disrupt global supply chains and drive up input costs for Indian manufacturers who heavily rely on them.
Passing on Costs May Not Be Enough
While Indian companies might attempt to pass on the increased costs to customers, analysts suggest that pricing flexibility—especially in international markets—remains limited. The highly competitive and price-sensitive nature of the US generics market could make it difficult for Indian players to raise prices without risking their market share.
Profit Margins Under Pressure
Even though the US tariff has not imposed direct on Indian exports, rising raw material costs are likely to put downward pressure on profit margins. Experts caution that unless companies mitigate cost escalation through operational efficiencies or alternate sourcing, they could suffer a significant hit to their margins.
Compliance Costs Add to the Burden
Compounding the challenge, Indian pharma companies are already under close regulatory scrutiny in the US regarding quality and compliance. Maintaining good manufacturing practices and regulatory approvals may lead to additional expenditures, further impacting profitability.
Short-Term Pain, Long-Term Opportunity?
Despite the short-term challenges, the situation may create a long-term opportunity for India to strengthen its domestic API manufacturing capabilities. However, hurdles such as high capital requirements, technological gaps, and limited infrastructure must be overcome. Government initiatives like the Production Linked Incentive (PLI) scheme for APIs could offer a buffer by encouraging investment in local manufacturing and reducing over-reliance on Chinese imports.
Recalibrating Strategy for Resilience
Indian pharma players such as Sun Pharma, Cipla, and Dr. Reddy’s Laboratories may need to revisit their procurement strategies and diversify their sourcing models. As reported by knnindia.co.in, investing in domestic production and fostering supply chain resilience will be key to navigating the evolving global trade landscape.
